Lineage Cell Therapeutics (LCTX) Operating Margin Growth (5y) (2015 - 2026)

Lineage Cell Therapeutics (LCTX) Operating Margin Growth (5y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Lineage Cell Therapeutics 270.61 Mn 212.77 Mn 1.07 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 54,811.00
Mar 31, 2026 136,290.00
Dec 31, 2025 155,781.00
Sep 30, 2025 107,491.00
Jun 30, 2025 94,318.00
Mar 31, 2025 101,399.00
Dec 31, 2024 37,557.00
Sep 30, 2024 138,375.00
Jun 30, 2024 97,240.00
Mar 31, 2024 91,382.00
Dec 31, 2023 102,868.00
Sep 30, 2023 51,656.00
Jun 30, 2023 20,323.00
Mar 31, 2023 146,014.00
Dec 31, 2022 66,527.00
Sep 30, 2022 40,633.00
Jun 30, 2022 218,467.00
Mar 31, 2022 325,985.00
Dec 31, 2021 96,374.00
Sep 30, 2021 36,163.00